Skip to content

Cancer Health Center

Font Size

Celebrex May Slow, Prevent Skin Cancers

Study Shows High-Risk Patients Had Fewer Basal Cell Cancers After Taking Celebrex
WebMD Health News
Reviewed by Louise Chang, MD

Jan. 5, 2009 -- There is mounting evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) may help prevent or slow the growth of non-melanoma skin cancers.

In a study published today, the Cox-2 arthritis drug Celebrex was found to reduce the growth of basal cell skin cancers by 50% in some patients with a rare genetic condition that makes them highly susceptible to the tumors.

And in a separate study reported last May, people who took Celebrex daily for nine months had 60% fewer non-melanoma skin cancers than people who did not take the drug.

Celebrex and other Cox-2 inhibitors act on the cyclooxygenase-2 enzyme involved in inflammation.

Stanford University assistant professor of dermatology Jean Y. Tang, MD, PhD, says the findings suggest a role for the cyclooxygenase enzyme in the development of basal cell carcinoma and possibly other non-melanoma skin cancers.

"Basal cell carcinomas are the most common cancer in the United States," she says. "Even though these tumors are not lethal they can have a big impact on quality of life, and we have no way to treat them short of surgical removal."

Study Ended Early Amid Vioxx Concerns

Even if Celebrex does slow skin cancer growth, it is probably not an appropriate preventive treatment for most people, Tang says.

"We certainly aren't recommending that people take this drug to reduce their risk for basal cell carcinomas," she says.

That is because of concerns about an increase in heart attack and stroke risk associated with the use of Cox-2 drugs. The Cox-2 drug Vioxx was withdrawn from the market by its manufacturer, Merck, in 2004 after studies linked its long-term use to an increase in deaths due to heart attack, stroke, and other cardiovascular events.

The study conducted by Tang, along with Ervin H. Epstein, Jr. of the Children's Hospital Oakland, was begun in 2001, before the cardiovascular risks were publicly reported.

The study included 60 patients with a very rare genetic condition known as Gorlin syndrome. Gorlin's patients can develop hundreds and even thousands of basal cell carcinomas over the course of their lives.

The study participants were treated with a standard therapeutic dose of Celebrex (200 milligrams, twice a day) or a placebo. Neither the patients nor the investigators knew which treatment was being given.

Today on WebMD

Colorectal cancer cells
A common one in both men and women.
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Real Cancer Perspectives
Jennifer Goodman Linn self-portrait
what is your cancer risk
colorectal cancer treatment advances
breast cancer overview slideshow
prostate cancer overview
lung cancer overview slideshow
ovarian cancer overview slideshow
Actor Michael Douglas